As of November 6, 2026, 5 holders' latest Schedule 13D or 13G filings report owning 5% or more of Keenova Therapeutics plc. The largest reported stake is GoldenTree Asset Management LP's, at 21.3%. 12 filings are on record since August 4, 2025 (Schedule 13D/A, October 6, 2026).
Sell to companies like Keenova Therapeutics plc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: GoldenTree Asset Management LP · Sole voting: 0 · Shared voting: 8,389,212 · Sole dispositive: 0 · Shared dispositive: 8,389,212 · SCHEDULE 13D/A, 2026-10-06
- · Holder: Silver Point Capital, L.P. · Percent: 15.2% · SCHEDULE 13D/A
- · Holder: Marathon Asset Management Gp, L.L.C. · Percent: 6.8% · SCHEDULE 13G/A
- · Holder: Silver Point Capital, L.P. · Percent: 14.2% · SCHEDULE 13D/A
- · Holder: Hein Park Capital Management LP · Percent: 5.5% · SCHEDULE 13G
Keenova Therapeutics plc has 12 Schedule 13D or 13G filings on record since 2025-08-04. 5 holders' latest filing reports 5% or more of ordinary shares, par value $0.01 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| GoldenTree Asset Management LP | 21.3% | 8,389,212 | SCHEDULE 13D/A, 2026-10-06 | 2026-09-24 |
| Silver Point Capital, L.P. | 15.2% | 6,035,214 | SCHEDULE 13D/A, 2026-05-22 | 2026-05-20 |
| Marathon Asset Management Gp, L.L.C. | 6.8% | 2,710,229 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 |
| Hein Park Capital Management LP | 5.5% | 2,146,733 | SCHEDULE 13G, 2026-02-13 | 2025-12-31 |
| Hudson Bay Capital Management LP | 5.19% | 2,049,739 | SCHEDULE 13G/A, 2026-02-11 | 2025-12-31 |
Holding shares or following this stake? See who's behind Keenova Therapeutics plc and the warning signs.
Free to see. No signup.
Keep reading
More on Keenova Therapeutics plc and the records around it.
Companies that share a holder
- MARATHON ASSET MANAGEMENT GP, L.L.C. also filed stake reports on 2 other companies: GRAFTECH INTERNATIONAL LTD (May 2026)
- GoldenTree Asset Management LP also filed stake reports on 4 other companies: QVC GROUP, INC. (Oct 2026), GoldenTree Opportunistic Credit Fund (Jun 2026), United Parks & Resorts Inc. (Feb 2026)
- Silver Point Capital, L.P. also filed stake reports on 9 other companies: Smart Share Global Limited (Aug 2026), Cool Company Ltd. (May 2026), Veradigm Inc. (May 2026)
Watch Keenova Therapeutics plc
Get an email when Keenova Therapeutics plc files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Keenova Therapeutics plc?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Keenova Therapeutics plc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Keenova Therapeutics plc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
12 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| GoldenTree Asset Management LP | 0 | 8,389,212 | 0 | 8,389,212 | SCHEDULE 13D/A, 2026-10-06 |
| GoldenTree Asset Management LLC | 0 | 8,389,212 | 0 | 8,389,212 | SCHEDULE 13D/A, 2026-10-06 |
| Steven A. Tananbaum | 53,615 | 8,389,212 | 53,615 | 8,389,212 | SCHEDULE 13D/A, 2026-10-06 |
The latest filing identifies Keenova Therapeutics plc by CUSIP G5890A102 and gives its principal executive office as College Business & Technology Park, Cruiserath Road, Blanchardstown, Dublin (SCHEDULE 13D/A, 2026-10-06).
Source of funds (Item 3)
Item 3 of the Schedule 13D is hereby amended and supplemented by the following: On September 24, 2026, the Reporting Persons purchased an aggregate of 463,000 Ordinary Shares for aggregate consideration of $42,133,000 using working capital.GoldenTree Asset Management LP, SCHEDULE 13D/A, 2026-10-06
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-04 | Hein Park Capital Management LP | 4.9% | SCHEDULE 13D/A |
| 2025-08-07 | Hudson Bay Capital Management LP | 6.3% | SCHEDULE 13G/A |
| 2025-08-07 | GoldenTree Asset Management LP | 20.2% | SCHEDULE 13D |
| 2025-11-05 | Silver Point Capital, L.P. | 10.7% | SCHEDULE 13D/A |
| 2025-11-14 | Marathon Asset Management Gp, L.L.C. | 7.7% | SCHEDULE 13G/A |
| 2025-12-10 | Silver Point Capital, L.P. | 11.9% | SCHEDULE 13D/A |
| 2026-02-11 | Hudson Bay Capital Management LP | 5.19% | SCHEDULE 13G/A |
| 2026-02-13 | Hein Park Capital Management LP | 5.5% | SCHEDULE 13G |
| 2026-04-17 | Silver Point Capital, L.P. | 14.2% | SCHEDULE 13D/A |
| 2026-05-15 | Marathon Asset Management Gp, L.L.C. | 6.8% | SCHEDULE 13G/A |
| 2026-05-22 | Silver Point Capital, L.P. | 15.2% | SCHEDULE 13D/A |
| 2026-10-06 | GoldenTree Asset Management LP | 21.3% | SCHEDULE 13D/A |
Questions about who owns Keenova Therapeutics plc
Who owns Keenova Therapeutics plc?
On this page, 5 holders' latest ownership filings report 5% or more of Keenova Therapeutics plc: GoldenTree Asset Management LP (21.3%, Schedule 13D/A, filed 2026-10-06), Silver Point Capital, L.P. (15.2%, Schedule 13D/A, filed 2026-05-22), Marathon Asset Management Gp, L.L.C. (6.8%, Schedule 13G/A, filed 2026-05-15), Hein Park Capital Management LP (5.5%, Schedule 13G, filed 2026-02-13) and Hudson Bay Capital Management LP (5.19%, Schedule 13G/A, filed 2026-02-11).
Who are the largest shareholders of Keenova Therapeutics plc?
By the share each holder's latest filing reports, the largest holders of Keenova Therapeutics plc on this page are GoldenTree Asset Management LP (21.3%), Silver Point Capital, L.P. (15.2%) and Marathon Asset Management Gp, L.L.C. (6.8%).
When did GoldenTree Asset Management LP buy into Keenova Therapeutics plc?
The filings give report dates, not purchase dates. The earliest filing from GoldenTree Asset Management LP on this page is the Schedule 13D, filed 2025-08-07, reporting 20.2%; its latest, Schedule 13D/A filed 2026-10-06, reports 21.3%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Tools for this story
Each opens in a new tab, filled in for Keenova Therapeutics plc. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.